c-Myc (MYC) (NM_002467) Human Recombinant Protein

Snippet: ine, spleen, and heart at gross and histological levels (Figure S9F, Supporting Information). 3 Discussion Substantial evidence has highlighted the critical role of c‐Myc oncoprotein in driving tumorigenesis in a majority of human cancers, but no drugs are clinically available for the c‐Myc direct targeting yet. Several small‐molecule c‐Myc inhibitors were reported to cause a reduction of;200 ng recombinant c-Myc protein (Origene, TP760019, purity 80%) were incubated with 0.34 µg WBC100-FITC or with the equal mole FITC in 500 µL PBS overnight at 4 ℃

Snippet: its interactions with intracellular signaling and functional proteins16–19. TRIB3 is emerging as a potential therapeutic target for cancer because abrogating its expression dramatically reduces tumorigenesis and cancer progression17–22. Interestingly, the expression of TRIB2, another member of the pseudokinase family, is elevated in T-cell acute lymphoblastic leukemia (T-ALL)23, and TRIB2 has

Snippet: polymerase (New England BioLabs) and then cloned in frame with either EGFP (pEGFP-N1, Clontech, in BglII and AgeI restriction sites), or c-MYC (pCMV6-Entry, Origene, in NheI (OriGene) to generate the vector pCMV6-HIS-HA-hFUS wt , expressing the hFUS gene

Snippet: …Human RALA/p65, URGCP and c-myc cDNAs were purchased from OriGene (USA) and inserted into pLenti-C-mGFP vectors. ...;... …Human RALA/p65, URGCP and c-myc cDNAs were purchased from OriGene (USA) and inserted into pLenti-C-mGFP vectors.

Snippet: Identified in 1993, microRNAs (miRNAs) are a short class of noncoding RNA molecules (~22 nucleotides [nt]), which bind to the 3′UTR of ... with PmeI and FseI and ligated into an expression reporter plasmid pCMV6-VKORC1 with a c-myc tag (Origene Technologies, Rockville